Preferred Label : Long-acting Release Pasireotide;
NCIt synonyms : SOM230 LAR; LAR Pasireotide;
NCIt definition : A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting
cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration
of the LAR formulation of pasireotide, this somatostatin analog strongly binds to
and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to
an inhibition in the secretion of human growth hormone (hGH) and results in decreased
production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated
cell signaling pathways. This may lead to an inhibition in tumor cell growth and an
increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent
causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition
of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which
results in many unwanted symptoms. This agent may also block other key survival pathways
such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein
kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth
factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in
VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less
frequent administration as compared to the original form of this agent. SSTRs are
overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.;
NCI Metathesaurus CUI : CL458369;
Origin ID : C113656;
UMLS CUI : C3826869;
Semantic type(s)
- concept_is_in_subset
- has_target
